Literature DB >> 23333234

Post-injury conditioning with lipopolysaccharide or lipooligosaccharide reduces inflammation in the brain.

Deborah Bingham1, Constance M John, Jack Levin, S Scott Panter, Gary A Jarvis.   

Abstract

BACKGROUND: Traumatic brain injury (TBI) is a leading cause of mortality and disability in the Western world. The first stage of TBI results from the mechanical damage from an impact or blast. A second stage occurs as an inflammatory response to the primary injury and presents an opportunity for clinical intervention. In this study, we investigated the effect of pre- and post-injury treatment with lipopolysaccharide (LPS) from Escherichia coli and lipooligosaccharide (LOS) from Neisseria meningitidis on levels of cerebral inflammatory cells, circulating blood cells, and pro- and anti-inflammatory cytokine levels in a rat model of neuroinflammation induced by intrastriatal injection of IL-1β to mimic the second stage of TBI.
METHODS: LPS or LOS was administered intravenously (IV) or intranasally (IN) 2h pre- or post-injection of IL-1β. The rats were euthanized 12h following IL-1β injection. Brain sections were immunostained with antibody to ED-1, a microglia cell marker. Cells in whole blood were assessed with a VetScan HM2 analyzer, and cytokine levels in sera were analyzed with a Bio-Plex system.
RESULTS: Pre- and post-injury IV administration of LPS or LOS significantly reduced microglia in the brain, and IN pre-treatment with LPS or LOS showed a statistical trend towards reducing microglia. Pre- and post-treatment IV with LOS increased circulating levels of IL-2 and IL-4, whereas IN post-treatment with LPS reduced levels of the inflammatory cytokines, TNF-α and IFN-γ.
CONCLUSIONS: The findings strongly support continued investigation of post-conditioning with LPS or LOS as potential neuroprotective treatments for neuroinflammation from TBI. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23333234     DOI: 10.1016/j.jneuroim.2012.12.009

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  4 in total

Review 1.  Preconditioning provides neuroprotection in models of CNS disease: paradigms and clinical significance.

Authors:  R Anne Stetler; Rehana K Leak; Yu Gan; Peiying Li; Feng Zhang; Xiaoming Hu; Zheng Jing; Jun Chen; Michael J Zigmond; Yanqin Gao
Journal:  Prog Neurobiol       Date:  2014-01-02       Impact factor: 11.685

2.  Glial cell responses in a murine multifactorial perinatal brain injury model.

Authors:  Miriam Domowicz; Natasha L Wadlington; Judith G Henry; Kasandra Diaz; Miranda J Munoz; Nancy B Schwartz
Journal:  Brain Res       Date:  2017-12-21       Impact factor: 3.252

3.  Appearance of claudin-5+ leukocytes in the central nervous system during neuroinflammation: a novel role for endothelial-derived extracellular vesicles.

Authors:  Debayon Paul; Valentina Baena; Shujun Ge; Xi Jiang; Evan R Jellison; Timothy Kiprono; Dritan Agalliu; Joel S Pachter
Journal:  J Neuroinflammation       Date:  2016-11-16       Impact factor: 8.322

4.  Remifentanil ameliorates intestinal ischemia-reperfusion injury.

Authors:  Steven S C Cho; Ina Rudloff; Philip J Berger; Michael G Irwin; Marcel F Nold; Wei Cheng; Claudia A Nold-Petry
Journal:  BMC Gastroenterol       Date:  2013-04-22       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.